ReviewCurrent infectious disease reports2017
Polymyxin Resistance in Gram-negative Pathogens.
Review in Current infectious disease reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 1 synthesis or guideline pooled it, 137 citations in OpenAlex.
- Clinical outcomes and adverse events associated with intravenous polymyxin-containing therapy in hospitalized children with resistant Gram-negative infections: a systematic review and meta-analysis.Frontiers in pediatrics · 2026Pooled it
- Species-dependent in polymyxin B heteroresistance: genomic insights into adaptive evolution in Enterobacteriaceae.Annals of clinical microbiology and antimicrobials · 2026Article
- Urinary Tract Infections in Children - Microbiological Challenges and Mechanisms of Bacterial Resistance.Maedica · 2026Review
- An antimicrobial peptide as a potential therapy for bacterial pneumonia that alleviates antimicrobial resistance.Nature communications · 2025Article
- Natural compounds for colistin-resistant Acinetobacter baumannii biofilm control: eugenol, cinnamaldehyde, and carvacrol.Molecular biology reports · 2025Article
- Antibacterial and antibiofilm efficacy of eugenol, carvacrol, and cinnamaldehyde against colistin-resistant Klebsiella pneumoniae.Molecular biology reports · 2025Article
- Mutations in the essential outer membrane protein BamA contribute to Escherichia coli resistance to the antimicrobial peptide TAT-RasGAPThe Journal of biological chemistry · 2025Article
- Phytochemical profiling, antimicrobial, antibiofilm, and molecular docking ofFrontiers in pharmacology · 2025Article
- Emerging Mobile Colistin Resistance GeneInfection and drug resistance · 2025Article
- A comparison of two MALDI-TOF MS based assays for the detection of carbapenemases in Enterobacterales.Scientific reports · 2024Article
- Therapeutic Interventions forJournal of clinical medicine · 2024Review
- Article
- PmrB Y358N, E123D amino acid substitutions are not associated with colistin resistance but with phylogeny inMicrobiology spectrum · 2024Article
- β-lactam-induced OMV release promotes polymyxin tolerance inFrontiers in microbiology · 2024Article
- Colistin Resistance Mechanisms and Molecular Epidemiology ofInfection and drug resistance · 2024Article
- A novel major facilitator superfamily-type tripartite efflux system CprABC mediates resistance to polymyxins inFrontiers in microbiology · 2024Article
- Mid-dosing interval concentration is important for polymyxin B exposure and acute kidney injury in critically ill patients.CPT: pharmacometrics & systems pharmacology · 2023Article
- Eugenol works synergistically with colistin against colistin-resistantMicrobiology spectrum · 2023Article
- Review
- Stapled β-Hairpin Antimicrobial Peptides with Improved Stability and Activity against Drug-Resistant Gram-Negative Bacteria.Journal of medicinal chemistry · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe polymyxins are one of the last line antimicrobial classes to retain activity against multidrug-resistant Gram-negative bacilli. However, with the increased use of polymyxins in recent years, reports of resistance have also been increasing. We aimed to describe the mechanisms and occurrence of polymyxin resistance in Gram-negative organisms and propose strategies to overcome resistance. RECENT
findingsThe most common mechanism of acquired resistance to the polymyxins is via modification of the bacterial outer membrane lipopolysaccharide. Global epidemiological surveillance studies have reported the occurrence of polymyxin resistance to be most common in Enterobacteriaceae, specifically Enterobacter species and Acinetobacter baumannii. Prevalence of polymyxin-resistant Gram-negative organisms varies significantly by geographical location. Emergence of polymyxin resistance is of great concern, given the limited number of agents available to treat infections caused by multidrug-resistant Gram-negative organisms. Strategies to mitigate the development of polymyxin resistance include dose optimization and using polymyxin agents in combination with other highly active antimicrobial agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.